1	TITLE PAGE
2	
3	Title: U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022
4	Short Title: CDC support to international SARS-CoV-2 Serosurveys
5	
6	Authors:
7	Amen Ben Hamida <sup>1, 2¶</sup> *, Myrna Charles <sup>2,3¶</sup> , Christopher Murrill <sup>2,4¶</sup> , Olga Henao <sup>1, 2¶</sup> , Kathleen Gallagher <sup>1, 2¶</sup> .
8	
9	Affiliations:
10	<sup>1</sup> : Division of Global Health Protection, U.S. CDC, Atlanta, GA, USA.
11	<sup>2</sup> : COVID-19 International Task Force, U.S. CDC, Atlanta, GA, USA.
12	<sup>3</sup> : Influenza Division, U.S CDC, Atlanta, GA, USA.
13	<sup>4</sup> : Global Immunization Division, U.S. CDC, Atlanta, GA, USA.
14	
15	Corresponding author: <u>ABenHamida@cdc.gov</u> (ABH)
16	
17	Keywords: SARS-CoV-2, COVID-19, Pandemic, Seroprevalence, serosurvey, low- and middle-income
18	countries, U.S. CDC
19	
20	Abstract word count: 300 / 300
21	Manuscript word count: 2,898 (no restriction)
22	

# 23 ABSTRACT

24

SARS-CoV-2 seroprevalence surveys provide critical information to assess the burden of COVID-19, describe population immunity, and guide public health strategies. Early in the pandemic, most of these surveys were conducted within high-income countries, leaving significant knowledge gaps in low-and middle-income (LMI) countries. To address this gap, the U.S. Centers for Disease Control and Prevention (CDC) is supporting serosurveys internationally.

30

31 We conducted a descriptive analysis of international serosurveys supported by CDC during May 12, 2020– 32 February 28, 2022, using an internal tracker including data on the type of assistance provided, study 33 design, population surveyed, laboratory testing performed, and status of implementation. Since the 34 beginning of the pandemic, CDC has supported 72 serosurveys (77 serosurvey rounds) in 35 LMI countries by providing technical assistance (TA) on epidemiologic, statistical, and laboratory methods, financial 35 assistance (FA), or both. Among these serosurvey rounds, the majority (61%) received both TA and FA 36 37 from CDC, 30% received TA only, 3% received only FA, and 5% were part of informal reviews. Fifty-four percent of these serosurveys target the general population, 13% sample pregnant women, 7% sample 38 39 healthcare workers, 7% sample other special populations (internally displaced persons, patients, students, 40 and people living with HIV), and 18% assess multiple or other populations. These studies are in different 41 stages of implementation, ranging from protocol development to dissemination of results. They are 42 conducted under the leadership of local governments, who have ownership over the data, in collaboration 43 with international partners. Thirty-four surveys rounds have completed data collection.

44

45 CDC TA and FA of SARS-CoV-2 seroprevalence surveys will enhance the knowledge of the COVID-19

- 46 pandemic in almost three dozen LMI countries. Support for these surveys should account for current
- 47 limitations with interpreting results, focusing efforts on prospective cohorts, identifying, and forecasting
- 48 disease patterns over time, and helping understand antibody kinetics and correlates of protection.

# 49 INTRODUCTION

50

51	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) —the virus responsible for coronavirus
52	disease 2019 (COVID-19)— was first identified in December 2019 in Wuhan, China. After its rapid spread
53	to 20 additional countries in the first six weeks, on January 30, 2020, the World Health Organization (WHO)
54	declared COVID-19 a public health emergency of international concern (PHEIC, [1]). As of May 2022,
55	virtually all countries have been affected by COVID-19, resulting in more than 520 million COVID-19
56	confirmed cases and more than 6.2 million COVID-19-related deaths reported globally [2].

57

58 Seroprevalence surveys are generally conducted to assess the prevalence of pathogen-specific antibodies 59 in the serum and have been used extensively in the past to serve various public health purposes, including 60 to a) assess the prevalence and incidence of infections (e.g., human immunodeficiency virus [HIV], 61 hepatitis C and B viruses) [3-6]; b) identify populations that are susceptible to infections [7]; and c) inform 62 and sustain models for disease control, elimination, or eradication (e.g., measles, rubella, diphtheria, 63 poliomyelitis, and neonatal tetanus) [8-10].

64

SARS-CoV-2 seroprevalence surveys complement case-surveillance data. Case-surveillance generates data that is needed to assess the burden and severity of disease and identify transmission hotspots. However, these case reports are generally incomplete because many infections are not recognized; for example, if a) an individual is asymptomatic and does not seek health care, b) testing is not available and accessible, or c) identified cased are not appropriately reported to the national public health disease surveillance system. It is in this context that *SARS-CoV-2* seroprevalence surveys —which estimate the prevalence of *SARS-CoV-2* antibodies within a specific population and thus provide a useful proxy to assess previous

exposure to and/or vaccination against *SARS-CoV-2*— were initiated. Data from these surveys provide critical information for decision-makers to estimate the true burden of disease, describe population immunity over place and time, identify still-at-risk groups, help assess vaccination coverage, and ultimately guide public health strategies [11].

76

77 During the first year of the COVID-19 pandemic, most seroprevalence surveys were conducted within 78 high-income countries, leaving a significant knowledge gap in low- and middle-income (LMI) countries. 79 For example, among the 968 studies included in a systematic literature review of SARS-CoV-2 80 seroprevalence studies conducted during 2020, only 23% were from LMI countries [11-13]. To address 81 this gap, the U.S. Centers for Disease Prevention and Control (CDC) —along with multiple other 82 international actors, including WHO— started supporting seroprevalence studies in LMI settings in mid-83 2020. In this paper, we describe CDC's support of international seroprevalence surveys, define the 84 purpose and characteristics of the supported studies, discuss challenges with implementation and 85 propose possible steps moving forward to use seroprevalence data for public health action.

86

# 87 MATERIALS AND METHODS

88

On January 20, 2020, CDC activated its Emergency Operations Center in response to the COVID-19 pandemic to coordinate efforts to stop the transmission of *SARS-CoV-2* [14]. Consequently, an incident management structure was established, including the development and implementation of an incident action plan. Within the Incident Management System, an International Task Force, mostly consisting of CDC staff, was established to oversee CDC's role in the global response, including support for the implementation and monitoring of SARS-CoV-2 international seroprevalence studies. These studies were

95 funded mainly by the Coronavirus Aid, Relief, and Economic Security (CARES) Act, enacted on March 27,
96 2020 [14-16].

97

98 CDC-supported international seroprevalence studies are conducted under the leadership and guidance of 99 local government agencies that request CDC support (e.g., Ministries of Health or national public health 100 institutes) in close coordination with international stakeholders such as the WHO and Africa CDC. The 101 national governmental agencies retain total ownership over generated seroprevalence data. However, 102 limited and temporary access to seroprevalence data may be granted to CDC by the local authorities for 103 a specific task (e.g., data analysis). Technical support is generally provided through CDC offices in country. 104 It includes sharing of templates and guidance documents, assistance in protocol development, advice on 105 sampling methodology and laboratory techniques, staff training, data analysis and interpretation, and 106 dissemination of results.

107

108 To ensure some degree of standardization, whenever possible, CDC staff worked closely with WHO, and 109 encouraged countries to use the WHO UNITY protocol entitled "Population-based age-stratified 110 seroepidemiological investigation protocol for COVID-19 infection." The WHO UNITY protocol is part of a global seroepidemiological standardization initiative to increase evidence-based knowledge for action 111 112 [17]. The WHO UNITY criteria include: using an age-stratified sample from the general population; 113 following a cross-sectional, repeated cross-sectional, or a longitudinal survey design, including all 114 individuals regardless of acute or prior SARS-CoV-2 infection; and using a validated SARS-CoV-2 laboratory 115 test kit with sensitivity  $\geq$  90% and specificity  $\geq$  97% [17]. Survey designs were modified, as appropriate, to 116 accommodate country-specific needs.

117

118 To support the implementation of these surveys, in December 2020 CDC initiated an international

seroprevalence community of practice (a virtual monthly group call) to facilitate communication between CDC headquarters and country office staff engaging in seroprevalence work. This community of practice provided an opportunity to discuss and exchange information on topics including sampling, testing, and survey methods and to share ongoing progress, lessons learned, and available seroprevalence data.

124 In addition, we developed an Excel-based tracker for CDC-supported international seroprevalence 125 surveys, where project staff could update status of protocol development and implementation for each 126 survey. We reviewed information from the tracker and conducted a descriptive analysis of international 127 serosurveys supported by CDC during May 12, 2020–February 28, 2022. Variables included in the analysis 128 were: 1) type of assistance provided (e.g., only technical assistance, only financial assistance, both, 129 informal technical review [as defined by a one-time request for technical review or consultation for a 130 seroprevalence protocol that CDC is not actively engaged in]), 2) WHO region, 3) study design and 131 population surveyed, 4) laboratory testing used, 5) status of survey implementation and 6) status of 132 dissemination.

133

This activity was reviewed by CDC, deemed not to be research (ID: 0900f3eb81de998d), and was conducted consistent with applicable federal law and CDC policy (See e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.). The same applies for all the serosurveys described in this manuscript that have received CDC funding and CDC technical assistance or in which CDC staff are listed as co-authors.

139

140 **RESULTS** 

141


# 142 Type of CDC Support and geographic distribution

- 143 As of February 28, 2022, CDC has supported 72 COVID-19 international seroprevalence surveys,
- 144 corresponding to 77 survey rounds in 35 LMI countries.

145

- 146 Among these survey rounds, the majority (61%) receive both technical and financial assistance from CDC,
- 147 30% receive technical assistance only, and 3% receive only financial assistance. Six percent were part of
- 148 informal CDC reviews and technical assistance under the request of local authorities or external partners
- 149 (Figure 1).

- 151 Most surveys (54%) were conducted within the WHO African region, followed by 18% in the Americas
- region, 13% within the South-East Asian region, 7% in the Western Pacific region, and 4% for each of the
- 153 European and Eastern Mediterranean regions.
- 154
- 155 Figure 1: CDC Support to SARS-CoV-2 international seroprevalence surveys as of February 28, 2022 (N=
- 156 72 surveys / 77 survey rounds)



157

- 158 Note: TA: Technical assistance. Greyed countries did not receive CDC assistance.
- 159 Map developed using QGIS Software and Natural Earth base layer [18, 19].

160

### 161 Study design, population of interest, and WHO UNITY determination

Among the 72 seroprevalence surveys, 69% are based on a cross-sectional design (84% of which are using a single round, while the remaining 16% are using multiple rounds), 19% involve following longitudinal cohorts, and 10% are part of the establishment of COVID-19-specific sentinel surveillance (or being integrated within an already existing surveillance system). The remaining 1% are using a hybrid design customized to the target population (Table 1).

167

Forty-seven percent of the surveys involve targeting the general population through household-based surveys, and 7% involve targeting the general population through other means (e.g., recruiting from community venues or using a convenience sample); 13% involve sampling pregnant women; 7% involve following health care worker cohorts; and 7% are conducted among other special populations including people living with HIV, persons who were displaced, and students. The remaining 18% target multiple or other populations (e.g., truck drivers).

#### 174

- 175 Sixty-three percent of survey rounds have been assessed against WHO UNITY criteria. Among these, 79%
- involved methods aligned with the WHO UNITY criteria, and 21% did not.

177

### 178 Laboratory procedures

- 179 Among the 77 serosurvey rounds, 55% involved collecting blood via venipuncture, 25% involved using a
- 180 finger stick and 5% involved using remnant samples from other studies or ongoing cohorts. Eight percent
- 181 involved using multiple sample collection types, and 7% are yet to be determined. Seventeen percent
- involved using dried blood spots to store and transport specimens (Table 1).

183

The choice of antibody assays has been determined for 95% of serosurvey rounds. About half (55%) involved using an enzyme-linked immunosorbent assay (ELISA) to detect SARS-CoV-2 antibodies in serum, 20% involved using a multiplex assay, and 11% involved using a rapid test. The remaining 13% involved using multiple assays.

188

#### 189 **Progress to date**

Progress varies across countries. By February 28, 2022, among the 77 survey rounds, 16% are in the stage of protocol development, 16% are in the stage of preparing for data collection, 17% are in the stage of data analysis, 19% are in the stage of developing their deliverables, and 6% have their dissemination of results completed. The remaining 8% are either interrupted or CDC monitoring was discontinued (e.g., if CDC support was limited to an informal review) (Table 1).

Table 1: Summary of CDC-supported international SARS-CoV-2 seroprevalence surveys (N= 72 surveys /
 77 survey rounds)

Variables	N (%)
Type of Support (N=77 survey rounds)	
Technical and financial assistance	47 (61%)
Technical assistance only	23 (30%)
Financial assistance only	2 (3%)
Informal review	5 (6%)
Survey design (N=72 surveys)	
Cross-sectional (one-time survey)	42 (58%)
Repeated cross-sectional	8 (11%)
Longitudinal cohort	14 (19%)
Sentinel surveillance system*	7 (10%)
Hybrid design**	1 (1%)
Population surveyed (N=72 surveys)	
General population — Household survey	34 (47%)
General population — Other	5 (7%)
Healthcare workers	5 (7%)
People living with HIV	3 (4%)
Persons who were displaced	1 (1%)
Patients	1 (1%)
Students	1 (1%)
Pregnant	9 (13%)
Other	3 (4%)
Multiple	10 (14%)
WHO region (N=72 surveys)	
Africa	39 (54%)
Americas	13 (18%)
South-East Asia	9 (13%)
Europea	3 (4%)
Eastern Mediterranean	3 (4%)
Western Pacific	5 (7%)
Serologic testing (N=77 survey rounds)	
ELISA	40 (52%)
Antibody Rapid Test	8 (10%)
Multiplex	15 (19%)
Other/multiple	9 (12%)
To be determined	5 (6%)
Sample collection (N=77 survey rounds)	42 (55%)
Venipuncture	19 (25%)
Finger Stick	4 (5%)
Remnant samples	
Multiple	6 (7%)
Not yet determined	

Progress to date (N= 77 survey rounds)	
Protocol preparation and drafting	12 (16%)
Preparing for data collection	12 (16%)
Data collection ongoing	13 (17%)
Data analysis ongoing	14 (18%)
Drafting of deliverables ongoing	15 (19%)
Dissemination of results complete	5 (6%)
Serosurvey interrupted	2 (3%)
CDC monitoring discontinued	4 (5%)

Notes: \*Setting new sentinel surveillance systems (e.g., each month, recruiting the first 30 pregnant
women who are consulting at an ante-natal care clinic) or integrating seroprevalence within existing ones
(e.g., acute febrile illness sentinel surveillance system). \*\*Customized to the target population. ELISA:
enzyme-linked immunosorbent assay. Some variable percentages total 99% due to rounding.

202

### 203 **Dissemination of results**

To date, five manuscripts have been published. All five were cross-sectional, population-based surveys conducted in Africa (Table 2). As of February 2022, at least 15 other manuscripts from 10 countries are

206 currently being drafted.

207

As shown in Table 2, among the published data, SARS-CoV-2 seroprevalence estimates obtained mostly 208 209 during the first year of pandemic ranged from 2.1% in Zambia (6 districts, July 2020) to 34.7% in Kenya 210 (Nairobi, November 2020) [20-24]. Infection to reported cases ratios —which is the ratio of the number 211 of persons with previous infections as detected by seroprevalence studies (seropositive), to the number 212 of COVID-19 cases detected by the surveillance system during the same period— ranged from 21:1 in 213 Ethiopia (Addis Ababa, June–July 2020) to 295:1 in Senegal (National, October–November 2020) [20-24]. 214 215 Table 2: Published CDC-supported SARS-CoV-2 international seroprevalence studies by February 28, 2022 (N= 5) 216

Country	Geographic Scope	Design	Data Collection Period	Seroprevalence estimate	Infections to Cases Ratio	Referenc e
---------	---------------------	--------	------------------------------	----------------------------	---------------------------------	---------------

Ethiopia	14 major urban areas	Cross-sectional, population- based	June 24–July 8, 2020	3.5% (95% CI= 3.2%–3.8%)	21:1 (in Addis Ababa)	Tadesse et al. [ <u>20</u> ]
Kenya	Nairobi	Cross-sectional, population- based	November 2020	34.7% (95% CI= 31.8–37.6)	42:1	Ngere et al. [ <u>21</u> ]
Senegal	National	Cross-sectional, population- based	October 24– November 26, 2020	28.4% (95% CI= 26.1–30.8)	295:1	Talla et al. [ <u>22]</u>
Sierra Leone	National	Cross-sectional, population- based	March 2021	2.6% (95% CI= 1.9%–3.4%)	43:1	Barrie et al. [ <u>23</u> ]
Zambia	6 districts	Cross-sectional, population- based	July 4–27, 2020	Combined PCR and ELISA: 10.6% (95% CI= 7.3–13.9) ELISA: 2.1%	92:1	Mulenga et al. [ <u>24</u> ]
				(95% CI= 1.1– 3.1)		

217 Notes: Infections to case ratio: Number of possible SARS-CoV-2 infections estimated based on the

seroprevalence survey, divided by the number of COVID-19 cases detected by the national surveillance

system by the mid-point of the data collection period. ELISA: enzyme-linked immunosorbent assay. PCR:

- 220 polymerase chain reaction. CI: confidence interval.
- 221

# 222 **Discussion**

- 223 To supplement ongoing COVID-19 surveillance efforts in countries and ensure a thorough understanding
- of disease prevalence in LMI settings, CDC currently supports more than 70 seroprevalence studies in 35

countries. These surveys vary significantly in type of CDC support received, study design, the population
 surveyed, geographic distribution, laboratory method, and progress to date.

227

228 The heterogenicity in seroprevalence studies is expected given the varying situations and populations 229 surveyed both within and between countries and has been observed by others conducting a systematic 230 review to track SARS-CoV-2 serosurveys globally [12, 13]. In June 2021, a Canadian team published a systematic literature review of seroprevalence studies conducted during 2020, which included 968 unique 231 232 serosurveys with significant heterogenicity noted [11]. In order to make sense of this diversity in 233 seroprevalence studies and ensure comparability of results, several global initiatives have been launched 234 including the Serotracker website, designed by the same Canadian team, which conducts a systematic live 235 review of published SARS-CoV-2 seroprevalence studies, and displays results in an automated live 236 dashboard, allowing users to filter seroprevalence studies by several criteria including region, population 237 of interest, date of data collection, and test type [12, 13]. Additional initiatives include the WHO UNITY 238 approach and protocol templates for population-based seroprevalence surveys, which advocate for more 239 standardization and more rigorous methods while conducting serosurveys [17, 25]; and the WHO 240 statement on the reporting of seroprevalence studies, which aims to standardize reporting of 241 seroprevalence studies' results [26].

242

Five CDC-supported seroprevalence studies have been published to date; and at least 15 more had their results disseminated with MOH and are currently in the stage of developing their deliverables. All five published serosurveys were cross-sectional, population-based, and from countries in the WHO Africa region, with wide ranges in both SARS CoV-2 seroprevalence estimates (2.1% to 34.7%) and infection-tocases ratios (21:1 to 295:1) [20-24]. Of note, the previously mentioned systematic review and metaanalysis, including surveys conducted during 2020, estimated the median corrected SARS CoV-2

249 seroprevalence to be 0.6% in Southeast Asia, East Asia, and Oceania; 4.1% in high-income countries; 8.2% 250 in North Africa and the Middle East; 10.6% in Latin America and the Caribbean; 12.2% in Central Europe, 251 Eastern Europe, and Central Asia; 17.1% in South Asia; and 19.5% in Sub-Saharan Africa [11]. The extreme 252 variability in infection-to-case ratios from the CDC-supported surveys conducted in 2020 is consistent with 253 those reported in the literature, from a median of 6:1 in Central Europe, Eastern Europe, and Central Asia 254 to 217:1 in Southeast Asia, East Asia, and Oceania [11, 13]. This variability could be explained by different 255 factors including differences in clinical presentation, availability of testing, and mitigation measures 256 implemented in-countries.

257

258 Seroprevalence results provide critical information for decision makers to guide ongoing public health 259 strategies for the prevention and control of COVID-19. They allow for the assessment of the burden of 260 disease (e.g., cumulative incidence and true case-to-fatality ratio), identification of hidden hotspots, 261 quantification of the infection-to-case ratio, and estimation of vaccination coverage [11, 20-24]. When 262 coupled with other surveillance, clinical, and epidemiologic data, data from these surveys can also help 263 distinguish between a) a well-functioning surveillance system capturing most of the cases; b) a real gap in 264 the ability of public health system to identify, diagnose, and report symptomatic cases; and c) a less severe 265 clinical presentation which may lead to limited healthcare-seeking behavior.

266

Supporting the implementation of international seroprevalence surveys has numerous ongoing and emerging challenges. These include the ever-evolving nature of the pandemic, changes in mitigation strategies and shifting data needs to inform the response, limited resources to support these and other epidemiologic endeavors globally, and competing country priorities. Additionally, there is a clear need for serosurveys to adopt more efficient processes that allow for timelier implementation. These could include better integration with other ongoing surveillance or epidemiologic efforts; standardization of processes;

and real-time analysis and dissemination of results.

274

275	Several factors have also challenged the interpretation and usefulness of seroprevalence surveys leading
276	to a change over time in the questions these surveys can address. These include concerns about SARS-
277	CoV-2 cross-reactivity with other pathogens, the implementation of COVID-19 vaccination campaigns, the
278	emergence of new variants, reports of waning immunity, and un-defined correlates of protection (CoP).
279	
280	Several reports have been shared suggesting possible antigenic cross-reactivity between SARS-CoV-2 and
281	other pathogens including <i>Plasmodium</i> species, Dengue viruses, and other human coronaviruses; possibly
282	leading to a decreased specificity of SARS-CoV-2 serologic testing and a higher level of false positive
283	results, especially in the African region [27-32]. To help address this, CDC and WHO recommend using

serologic tests that have been independently validated and conducting an in-country validation or

verification whenever possible [<u>33</u>, <u>34</u>].

286

284

Early in the pandemic and before the introduction of SARS-CoV-2 vaccines, most seroprevalence survey 287 288 objectives focused on assessing the true burden of disease to help identify gaps in national public health 289 surveillance systems and identify at-risk populations [11, 17, 25]. The introduction of vaccines, critical in 290 slowing the spread of the virus and decreasing severity of the disease, has created challenges in the 291 design, implementation, and interpretation of SARS-CoV-2 serosurveys. Testing algorithms involving the 292 use of antibody assays with different targets (e.g. antibodies anti-nucleocapsid protein and antibodies 293 anti-Spike protein) have been developed to help distinguish between natural and vaccine-induced 294 immunity for vaccines that only target Spike protein-derived antigens (e.g., current mRNA and viral vector 295 vaccines) [35]. However, if the countries are using other vaccines or the survey design does not allow to 296 distinguish between natural and vaccine-induced immunity, the objectives of seroprevalence surveys

297 would be mostly limited to elucidating potentially at-risk populations and allocating scarce resources 298 (vaccines) efficiently [35]. Additionally, mounting evidence of waning antibodies with both natural and 299 vaccine-induced immunities challenges the ability to assess both the true burden of disease and 300 vaccination coverage [36-39]. Of note, infection severity, timing of testing, and the choice of antibody 301 assays all seem to significantly impact antibodies' detection over time [40]. CDC is currently working with 302 international partners to address the statistical, epidemiologic, and laboratory considerations of vaccine 303 introduction and to adapt seroprevalence protocols accordingly, based on WHO interim guidance and in-304 country specific needs and priorities.

305

Finally, the question of correlates of protection (CoP) for SARS-CoV2 is not resolved. Several studies have documented an inverse relationship between neutralizing antibody levels and incidence of infection, and a correlation between these antibody levels and vaccine efficacy suggests a possible relative CoP against infection that is likely defined by quantitative thresholds [35, 41-44]. However, most serosurveys underway are using qualitative assays to assess circulating antibodies. Cellular immunity, which is generally more durable and likely to be integral to CoP, is generally not assessed in these surveys due to technical and cost challenges [35, 41].

313

CDC technical assistance and financial support of SARS-CoV-2 international seroprevalence surveys contribute to strengthening local capacity to conduct epidemiologic surveillance and enhance the knowledge of the COVID-19 pandemic in almost three dozen LMI countries. Considering constantly evolving challenges to implementation and interpretation of seroprevalence results two years into the COVID-19 pandemic, there is a need for the global public health community to assess the best strategies for future SARS-CoV-2 seroprevalence efforts. These strategies could include developing a better understanding of antibody kinetics, identifying and forecasting epidemic patterns over time, and helping

assess CoP. These objectives may be attainable by relying on prospective cohorts, integrating COVID-19
 sero-surveillance with surveillance of other pathogens, and introducing quantitative testing of binding and
 neutralizing antibodies. Support for international seroprevalence surveys can help understand patterns
 of transmission, guide public health interventions, allocate resources strategically, and ultimately control
 the spread of the pandemic.

# 327 Disclaimer

The findings and conclusions in this study are those of the author(s) and do not necessarily represent the views of the U.S. Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease

330 Registry.

331

# 332 Acknowledgments

U.S. CDC Countries offices involved in seroprevalence work; National Ministries of Public Health, CDCs,
 Institutes for Public health, and other implementing partners; U.S. CDC Division of Global Health
 Protection, Global Epidemiology, Laboratory, and Surveillance Branch, Surveillance and Information
 Systems Team and Laboratory Team; U.S. CDC International Task Force, Epidemiology and Laboratory
 Teams; WHO Seroprevalence Team; SeroTracker team; and Africa CDC Seroprevalence Team.

338

339

# 340 **References**

World Health Organization (WHO). COVID-19 Public Health Emergency of International Concern
 (PHEIC) Global research and innovation forum [Internet]. 2020 [updated 2020 February 12; cited 2021
 November 23]. Available from: <u>https://www.who.int/publications/m/item/covid-19-public-health-</u>
 <u>emergency-of-international-concern-(pheic)-global-research-and-innovation-forum</u>.

World Health Organization (WHO). COVID-19 Explorer [Internet]. 2020 [updated 2022 May 18;
 cited 2022 May 18]. Available from: <u>https://worldhealthorg.shinyapps.io/covid/</u>.

Khokhar N, Gill ML, Malik GJ. General seroprevalence of hepatitis C and hepatitis B virus infections
 in population. J Coll Physicians Surg Pak. 2004;14(9):534-6.

Drain PK, Smith JS, Hughes JP, Halperin DT, Holmes KK. Correlates of National HIV Seroprevalence:
 An Ecologic Analysis of 122 Developing Countries. JAIDS Journal of Acquired Immune Deficiency
 Syndromes. 2004;35(4).

Abdool Karim Q, Abdool Karim SS, Singh B, Short R, Ngxongo S. Seroprevalence of HIV infection in
 rural South Africa. AIDS (London, England). 1992;6(12):1535-9.

Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New
 estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212-9.

Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis.
Epidemiology and Infection. 2004;132(6):1005-22.

PachÓN I, Amela C, De Ory F. Age-specific seroprevalence of poliomyelitis, diphtheria and tetanus
 antibodies in Spain. Epidemiology and Infection. 2002;129(3):535-41.

McQuillan GM, Kruszon-Moran D, Hyde TB, Forghani B, Bellini W, Dayan GH. Seroprevalence of
 Measles Antibody in the US Population, 1999–2004. The Journal of infectious diseases.
 2007;196(10):1459-64.

Winter AK, Martinez ME, Cutts FT, Moss WJ, Ferrari MJ, McKee A, et al. Benefits and Challenges
in Using Seroprevalence Data to Inform Models for Measles and Rubella Elimination. The Journal of
infectious diseases. 2018;218(3):355-64.

Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence of SARS CoV-2 antibodies: A systematic review and meta-analysis. PloS one. 2021;16(6):e0252617.

368 12. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard [Internet]. 2020 [updated 2021
 369 November 10; cited 2021 November 24]. Available from: <u>https://serotracker.com/en/Explore</u>.

Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E, et al. SeroTracker: a global SARS-CoV-2
seroprevalence dashboard. The Lancet Infectious diseases. 2021;21(4):e75-e6.

U.S. Centers for Disease Control and Prevention (CDC). CDC Emergency Operations Center
 Activations [Internet]. 2020 [updated January 20, 2020; cited November 26, 2021]. Available from:
 https://emergency.cdc.gov/recentincidents/.

375 15. Congress.gov. H.R.748 - CARES Act [Internet]. 2019 [updated March 27, 2020; cited November 26,
376 2021]. Available from: <u>https://www.congress.gov/bill/116th-congress/house-bill/748</u>.

Bipartisan Policy Center. U.S. Leadership in the COVID-19 Pandemic Response: Global Health is
U.S. Health [Internet]. 2020 [updated April 2020; cited November 26, 2021]. Available from:
<a href="https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2020/04/BPC\_Health\_COVID19-">https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2020/04/BPC\_Health\_COVID19-</a>
<a href="https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2020/04/BPC\_Health\_COVID19-">https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2020/04/BPC\_Health\_COVID19-</a>
<a href="https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2020/04/BPC\_Health\_COVID19-">https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2020/04/BPC\_Health\_COVID19-</a>

17. World Health Organization (WHO). Coronavirus disease (COVID-19) technical guidance: The Unity

382 Studies: Early Investigation Protocols [Internet]. 2020 [updated 2020 May 26; cited 2021 November 24].

383 Available from: <u>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-</u>
 384 guidance/early-investigations.

18. Natural Earth. Public Domain Map Dataset 2022 [cited May 25 2022]. Available from:
 https://www.naturalearthdata.com/about/terms-of-use/.

387 19. QGIS. A Free and Open Source Geographic Information System 2022 [cited May 25 2022].
388 Available from: <u>https://qgis.org/en/site/index.html</u>.

Tadesse EB, Endris AA, Solomon H, Alayu M, Kebede A, Eshetu K, et al. Seroprevalence and risk
 factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during
 July 2020. International journal of infectious diseases : IJID : official publication of the International Society
 for Infectious Diseases. 2021;111:179-85.

Ngere I, Dawa J, Hunsperger E, Otieno N, Masika M, Amoth P, et al. High seroprevalence of SARSCoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya. International
journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2021;112:25-34.

Talla C, Loucoubar C, Roka JL, Barry A, Ndiay S, Diarra M, et al. Seroprevalence of Anti-SARS-CoVAntibodies in Senegal: A National Population-Based Cross-Sectional Survey, between October and
November 2020 [PrePrint]. 2021 [updated September 17, 2021; cited November 29, 2021]. Available
from: http://dx.doi.org/10.2139/ssrn.3925475.

Barrie MB, Lakoh S, Kelly JD, Kanu JS, Squire JS, Koroma Z, et al. SARS-CoV-2 antibody prevalence
in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey. BMJ
Glob Health. 2021;6(11).

404 24. Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwingwa M, Yingst S, et al. Prevalence of SARS-CoV405 2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. The Lancet Global health.
406 2021;9(6):e773-e81.

Bergeri I, Lewis HC, Subissi L, Nardone A, Valenciano M, Cheng B, et al. Early epidemiological
investigations: World Health Organization UNITY protocols provide a standardized and timely
international investigation framework during the COVID-19 pandemic. Influenza and other respiratory
viruses. 2021;16(1), 7–13.

World Health Organization Seroepidemiology Technical Working G. ROSES-S: Statement from the
World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2. Influenza and
other respiratory viruses. 2021;15(5):561-8.

Yadouleton A, Sander AL, Moreira-Soto A, Tchibozo C, Hounkanrin G, Badou Y, et al. Limited
Specificity of Serologic Tests for SARS-CoV-2 Antibody Detection, Benin. Emerging infectious diseases.
2021;27(1).

Emmerich P, Murawski C, Ehmen C, von Possel R, Pekarek N, Oestereich L, et al. Limited specificity
of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin. Trop Med Int Health.
2021;26(6):621-31.

Lustig Y, Keler S, Kolodny R, Ben-Tal N, Atias-Varon D, Shlush E, et al. Potential Antigenic Crossreactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses.
Clin Infect Dis. 2021;73(7):e2444-e9.

423 30. Gold JE, Baumgartl WH, Okyay RA, Licht WE, Fidel PL, Jr., Noverr MC, et al. Analysis of Measles424 Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients. mBio. 2020;11(6).

Tso FY, Lidenge SJ, Pena PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High prevalence of preexisting serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoVin sub-Saharan Africa. International journal of infectious diseases : IJID : official publication of the
International Society for Infectious Diseases. 2021;102:577-83.

Masyeni S, Santoso MS, Widyaningsih PD, Asmara DW, Nainu F, Harapan H, et al. Serological crossreaction and coinfection of dengue and COVID-19 in Asia: Experience from Indonesia. International journal
of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2021;102:152-4.

433 33. NRL Science of Quality. Independent NRL contracted SARS-CoV-2 IVD assessments [Internet]. 434 2021 2021; 2021]. [updated November 29, cited November 29, Available from: 435 https://www.nrlquality.org.au/who-covid-evaluations-summary-of-results.

436 34. FIND The Global Alliance for Diagnostics. FIND Evaluation of SARS-CoV-2 Antibody Detection Tests
437 [Internet]. 2021 [updated April 30, 2021; cited November 29, 2021]. Available from:
438 https://www.finddx.org/sarscov2-eval-antibody/.

439 35. Duarte N, Yanes-Lane M, Arora RK, Bobrovitz N, Liu M, Bego MG, et al. Adapting Serosurveys for
440 the SARS-CoV-2 Vaccine Era. Open forum infectious diseases. 2022;9(2):ofab632.

36. Kojima N, Klausner JD. Protective immunity after recovery from SARS-CoV-2 infection. The Lancet
Infectious diseases. 2022;22(1):12-4.

37. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2
assessed for up to 8 months after infection. Science. 2021;371(6529).

38. Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan HX, et al. Evolution of immune responses
to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021;12(1):1162.

39. Stone M, Grebe E, Sulaeman H, Di Germanio C, Dave H, Kelly K, et al. Evaluation of Commercially
Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications.
Emerging infectious diseases. 2022;28(3):672-83.

450 40. Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, et al. SARS-CoV-2 antibody magnitude 451 and detectability are driven by disease severity, timing, and assay. Science Advances. 452 2021;7(31):eabh3409.

453 41. Perry J, Osman S, Wright J, Richard-Greenblatt M, Buchan SA, Sadarangani M, et al. Does a 454 humoral correlate of protection exist for SARS-CoV-2? A systematic review. medRxiv. 455 2022:2022.01.21.22269667.

456 42. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for 457 antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423-8.

43. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody
levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature
Medicine. 2021;27(7):1205-11.

461 44. Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralising antibody
462 titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis.
463 The Lancet Microbe. 2022;3(1):e52-e61.